![Big pharma, on the other hand, is facing an expected drop in revenue.](https://imagenes.elpais.com/resizer/v2/JXEHGFISSNACVASSU546RYG5B4.jpg?auth=efe0bc226b131cb0601887caaa1ac4aa4420489d6b503d21e50977e9802e18a2&width=414&height=233&smart=true)
Who wins and who loses with the end of patents on biopharmaceuticals?
A number of important drugs will lose their exclusivity, paving the way for generics and biosimilars
A number of important drugs will lose their exclusivity, paving the way for generics and biosimilars